BOSTON--(BUSINESS WIRE)--Jun. 14, 2018--
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
Vertex employees and The Vertex Foundation have together donated over $1
million through the Company’s new dollar-for-dollar matching gift
program. The funds demonstrate the Company’s long-term commitment to
giving back and to supporting employees’ deep commitment to
strengthening their communities.
The matching gift program launched on November 28, 2017 and was created
to extend the impact of employee donations to qualified nonprofit
organizations. The program is operated through The Vertex Foundation, a
501(c)(3) organization and long-term source of charitable giving, and is
part of Vertex’s sustained corporate giving commitment of $500 million
over the next 10 years. To date, more than 500 employees have
participated in the program, donating to 753 charities across the world
that support health care, human services, education and disaster relief,
among other causes.
“Giving back is in our DNA at Vertex, and our employees have a long
history of going the extra mile to improve the lives of patients,
students and their neighbors,” said Dr. Jeffrey Leiden, President,
Chairman and Chief Executive Officer of Vertex. “I’m proud that The
Vertex Foundation is able to help extend the impact of our employees’
giving and look forward to seeing the reach of these investments in the
causes they care about most.”
Vertex’s 10-year, $500 million corporate giving commitment is focused on
supporting the following areas:
-
The cystic fibrosis (CF) patient community globally, including
enabling access to our medicines;
-
Science, technology, engineering, arts and math (STEAM) education,
focused on underserved students and young women;
-
Developing young physicians and scientists; and
-
Strengthening our local communities, including fostering the
innovation ecosystem and supporting youth health and wellness.
About Vertex
Vertex is a global biotechnology company that
invests in scientific innovation to create transformative medicines for
people with serious and life-threatening diseases. In addition to
clinical development programs in CF, Vertex has more than a dozen
ongoing research programs focused on the underlying mechanisms of other
serious diseases.
Founded in 1989 in Cambridge, Mass., Vertex's headquarters is now
located in Boston'sInnovation District. Today, the company has research
and development sites and commercial offices in the United States,
Europe, Canada and Australia. Vertex is consistently recognized as one
of the industry's top places to work, including being named to Science
magazine's Top Employers in the life sciences ranking for eight years in
a row. For additional information and the latest updates from the
company, please visit www.vrtx.com.
For Funding Requests please visit https://www.vrtx.com/giving-back.
(VRTX-GEN)
View source version on businesswire.com: https://www.businesswire.com/news/home/20180614005157/en/
Source: Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Heather
Nichols, 617-341-6992
mediainfo@vrtx.com
